3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
28
Phase 2
25
Phase 3
8
Phase 1/2
5
Phase 4
2
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
2
Other hematologic neoplasm
2
Plasma cell
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Conditions
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Multiple Myeloma
1
Melanoma
1
Laryngeal Neoplasms
1
Hematologic Neoplasms
1
Glioma
1
Erdheim-Chester Disease
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Nivolumab
7
pembrolizumab
5
Ipilimumab
4
Interferon alpha-2
3
relatlimab
2
Etoposide
2
Drug Therapy
2
Dacarbazine
2
Cyclophosphamide
2
sargramostim
1
salicylhydroxamic acid
1
pertuzumab
1
peginterferon alfa-2b
1
peginterferon alfa-2a
1
molgramostim
1
green tea extract polyphenone E
1
fludarabine phosphate
1
entrectinib
1
cyclopropapyrroloindole
1
cobimetinib
1
atezolizumab
1
Whole-Body Irradiation
1
Vincristine
1
Vemurafenib
1
VAP-cyclo protocol
1
Triamcinolone Acetonide
1
Trastuzumab
1
Thiotepa
1
Temozolomide
1
Surgical Procedures, Operative
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Vemurafenib
×
Dermatologic
×
Clear all
NCT05768178
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled